Seasonal Allergy Market Gears Up to Surpass US$ 2.58 Billion by 2033-FMI Study

Seasonal Allergy Market

The most recent industry analysis by Future Market Insights places the worldwide seasonal allergy market estimated worth at US$ 1.15 billion in 2022. The market is predicted to develop at a compound annual growth rate (CAGR) of 7.8% to reach an estimated valuation of US$ 2.58 billion in 2033.

Changes in the length and ferocity of pollen seasons have an impact on allergy diseases such as rhinitis, conjunctivitis, and asthma. Children, the elderly, and people with reactive airway diseases like asthma are populations that are more susceptible to these negative health effects. Greenhouse gases are capable of evoking respiratory symptoms in people with asthma and chronic obstructive pulmonary disease, as well as contributing to premature mortality and long-term declines in lung function.

As a result of global climate change, an increasing number of people are currently experiencing allergy disorders brought on by pollen. Additionally, in the Asia-Pacific region as well as in Europe and America, seasonal and regional differences in pollen have shifted. Growing populations of allergenic plants have become a hazard to allergic kids as pollen sensitivity rates in children have recently increased.

By reducing the antiviral interferon response, pollen exposure reduces immunity to some seasonal respiratory infections. According to a new, extensive cohort study from South Korea, co-exposure to numerous seasonal environmental variables, such as ozone, rhinovirus, and tree pollen, is linked to asthma exacerbations in school-aged children.

Forecasting and eliminating the related danger for human health in the future and taking suitable actions to reduce it are vital, especially in light of the impact of climate change on long-term trends in pollen levels and developing virus infection.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17113

Key Takeaways:

• Tablets/Capsules segment is set to lead in terms of the form of seasonal allergy with a projected market value share of around 33.6% by 2033, it is simple to swallow tablets and capsules because they don’t need to be prepared or measured.
• OTC medications are the most popular prescription type because they are easily accessible without a prescription and because drug stores make it simple to obtain the often-prescribed allergy medications. In 2022, OTC by prescription held a 76.3% market share.
• There are numerous treatments, but antihistamines dominate the therapy segment with a predominant share of 46.0%.
• By distribution channel, hospital pharmacies held a share of around 35.9% in 2022. Hospital pharmacies have access to an extensive selection of specialty drugs that may not be offered by retail pharmacies.
• North America held one-third value share of the global market in 2022, owing to the increasing prevalence of seasonal allergies in the region.

“With the increasing prevalence of seasonal allergies and the growing awareness about available treatment options, the market for seasonal allergy treatment is expected to witness significant growth in the coming years. Moreover, technological advancements in the development of novel therapies and the rising demand for personalized medicine are anticipated to shape the future trends in the seasonal allergy treatment market,”Says an analyst of Future Market Insights.

Market Competition

Seasonal allergy is a market that is fragmented with multiple key players. The market participants are concentrated on developing, launching, and receiving approvals for pharmaceutical products in order to enhance treatment outcomes. Manufacturers are also anticipating mergers and partnerships.

• ALK Abello and a major pharmaceutical company, Windgap Medical, announced a partnership in August 2019 to introduce a new generation of epinephrine auto-injector pens in the United States. This aided the business in increasing its market share in the United States
• Anergis and Virometix agreed to a research partnership in July 2020 to examine synthetic virus-like particles for extremely quick allergy shots.

Key companies profiled in seasonal allergy industry are Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma, ALK Abello, Stallergenes Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca, and others.

Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-17113

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the Seasonal Allergy market in its latest study, presenting a historical demand assessment of 2018 to 2022 and projections for 2023 to 2033. The global Seasonal Allergy market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Segments:

By Form:

• Tablets/Capsules
• Liquid
• Creams & Lotions
• Drops
• Spray

By Prescription:

• OTC
• Prescription based

By Route of Administration:

• Oral
• Intranasal
• Sublingual
• Sub Cutaneous
• Intravenous

By Treatment:

• Antihistamines
• Decongestants
• Nasal Corticosteroids
• Allergen Immunotherapy
• Leukotriene Receptor Antagonists

By Distribution Channel:

• Hospital Pharmacies
• Supermarkets/Hypermarkets
• Online Pharmacies
• Retail Pharmacies
• Speciality Clinics
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube